AstraZeneca PLC

AZN

Company Profile

  • Business description

    A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.

  • Contact

    1 Francis Crick Avenue
    Cambridge Biomedical Campus
    CambridgeCB2 0AA
    GBR

    T: +44 2037495000

    E: [email protected]

    https://www.astrazeneca.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - General

    Fiscal Year End

    31 December 2025

    Employees

    94,300

AstraZeneca PLC News & Analysis

markets

What are emerging and frontier markets?

Power blocs, frontier stocks and investor shocks explained as the world becomes more complex 
stocks

Magnificent Seven vs. the ‘Granolas’: How does Europe’s version stack up?

‘Granolas’ stocks are profitable, diversified, cheap—and posting big returns.
stocks

Best international companies to own: 2023 Edition

These companies from various corners of the globe are well positioned for the future.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,126.902.50-0.03%
CAC 407,742.7343.810.57%
DAX 4023,824.10227.120.96%
Dow JONES (US)45,473.77147.52-0.32%
FTSE 1009,232.9224.710.27%
HKSE25,633.91215.930.85%
NASDAQ21,870.43162.730.75%
Nikkei 22543,643.81625.061.45%
NZX 50 Index13,281.1457.610.44%
S&P 5006,505.2023.700.37%
S&P/ASX 2008,849.605.60-0.06%
SSE Composite Index3,826.8414.330.38%

Market Movers